High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 101–200 of 1,016
Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning
Arbab, M., Shen, M. W., Mok, B., Wilson, C., Matuszek, Ż., Cassa, C. A., & Liu, D. R. (2020) · Cell · doi:10.1016/j.cell.2020.05.037 · Cited by 294
CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity
Lazzarotto, C. R., Malinin, N. L., Li, Y., Zhang, R., Yang, Y., Lee, G., Cowley, E., He, Y., Lan, X., Jividen, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0555-7 · Cited by 284
Self-citationA conformational checkpoint between DNA binding and cleavage by CRISPR-Cas9
Dagdas, Y. S., Chen, J. S., Sternberg, S. H., Doudna, J. A., & Yildiz, A. (2017) · Science Advances · doi:10.1126/sciadv.aao0027 · Cited by 293
“Efforts are in progress (15, 16) to enhance the specificity of DNA targeting by Cas9 for potential therapeutic applications (17, 18), which requires detailed mechanistic understanding of substrate-dependent activation of Cas9 for DNA cleavage.”
BackgroundRecent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 292
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections
van Diemen, F. R., Kruse, E. M., Hooykaas, M. J. G., Bruggeling, C. E., Schürch, A. C., van Ham, P. M., Imhof, S. M., Nijhuis, M., Wiertz, E. J. H. J., & Lebbink, R. J. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005701 · Cited by 290
“Another strategy is to engineer Cas9 derivatives by mutagenesis that have reduced off-tar-geting potential, yet retain their on-targeting activity [72 – 74].”
Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors
Huang, T. P., Zhao, K. T., Miller, S. M., Gaudelli, N. M., Oakes, B. L., Fellmann, C., Savage, D. F., & Liu, D. R. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0134-y · Cited by 281
“These variants included evolved S. pyogenes Cas9 variants SpCas9-VQR/SpCas9-VRQR (PAM: NGA) 24,25 , SpCas9-VRER (PAM: NGCG) 24 , xCas9 (PAM: NGN) 19 , SpCas9-NG (PAM: NG) 26 , S. aureus Cas9 (PAM: NNGRRT) 27,28 and its modified variant KKH (PAM: NNNRRT) 29 , and L. bacterium Cas12a (Cpf1, PAM: TTTV…”
Predicting the efficiency of prime editing guide RNAs in human cells
Kim, H. K., Yu, G., Park, J., Min, S., Lee, S., Yoon, S., & Kim, H. H. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0677-y · Cited by 276
Structural basis for mismatch surveillance by CRISPR–Cas9
Bravo, J. P. K., Liu, M.-S., Hibshman, G. N., Dangerfield, T. L., Jung, K., McCool, R. S., Johnson, K. A., & Taylor, D. W. (2022) · Nature · doi:10.1038/s41586-022-04470-1 · Cited by 272
Neugebauer, M. E., Hsu, A., Arbab, M., Krasnow, N. A., McElroy, A. N., Pandey, S., Doman, J. L., Huang, T. P., Raguram, A., Banskota, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01533-6 · Cited by 272
Genome-wide target specificities of CRISPR RNA-guided programmable deaminases
Kim, D., Lim, K., Kim, S.-T., Yoon, S.-H., Kim, K., Ryu, S.-M., & Kim, J.-S. (2017) · Nature Biotechnology · doi:10.1038/nbt.3852 · Cited by 276
Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
Ryan, D. E., Taussig, D., Steinfeld, I., Phadnis, S. M., Lunstad, B. D., Singh, M., Vuong, X., Okochi, K. D., McCaffrey, R., Olesiak, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1199 · Cited by 280
Precision genome editing in plants: state-of-the-art in CRISPR/Cas9-based genome engineering
Wada, N., Ueta, R., Osakabe, Y., & Osakabe, K. (2020) · BMC Plant Biology · doi:10.1186/s12870-020-02385-5 · Cited by 266
microRNA target prediction programs predict many false positives
Pinzón, N., Li, B., Martinez, L., Sergeeva, A., Presumey, J., Apparailly, F., & Seitz, H. (2017) · Genome Research · doi:10.1101/gr.205146.116 · Cited by 273
“Inordertoverifyexperimentallythetitratingeffectof Tmsb4x on miR-1a/miR-206 availability, we mutated its 3 ′ UTR in C2C12 cells with high-fidelity nuclease “ SpCas9-HF1 ” (Kleinstiver et al. 2016).”
CRISPR/cas systems redefine nucleic acid detection: Principles and methods
Wang, M., Zhang, R., & Li, J. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112430 · Cited by 268
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataeijannati, Y., Sun, X., Dong, L., Li, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14716 · Cited by 271
Reducing resistance allele formation in CRISPR gene drive
Champer, J., Liu, J., Oh, S. Y., Reeves, R., Luthra, A., Oakes, N., Clark, A. G., & Messer, P. W. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720354115 · Cited by 274
Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9
Singh, D., Sternberg, S. H., Fei, J., Doudna, J. A., & Ha, T. (2016) · Nature Communications · doi:10.1038/ncomms12778 · Cited by 263
Cas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editing
Swarts, D. C., & Jinek, M. (2018) · WIREs RNA · doi:10.1002/wrna.1481 · Cited by 267
Aird, E. J., Lovendahl, K. N., St. Martin, A., Harris, R. S., & Gordon, W. R. (2018) · Communications Biology · doi:10.1038/s42003-018-0054-2 · Cited by 250
Long, C., Li, H., Tiburcy, M., Rodriguez-Caycedo, C., Kyrychenko, V., Zhou, H., Zhang, Y., Min, Y.-L., Shelton, J. M., Mammen, P. P. A., et al. (2018) · Science Advances · doi:10.1126/sciadv.aap9004 · Cited by 258
De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3480 · Cited by 258
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges
Mout, R., Ray, M., Lee, Y.-W., Scaletti, F., & Rotello, V. M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00057 · Cited by 243
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H.-X., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 248
Ormond, K. E., Mortlock, D. P., Scholes, D. T., Bombard, Y., Brody, L. C., Faucett, W. A., Garrison, N. A., Hercher, L., Isasi, R., Middleton, A., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.012 · Cited by 252
Refining strategies to translate genome editing to the clinic
Cornu, T. I., Mussolino, C., & Cathomen, T. (2017) · Nature Medicine · doi:10.1038/nm.4313 · Cited by 252
Application of CRISPR/Cas9-mediated gene editing for abiotic stress management in crop plants
Kumar, M., Prusty, M. R., Pandey, M. K., Singh, P. K., Bohra, A., Guo, B., & Varshney, R. K. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1157678 · Cited by 232
“For example, high fidelity SpCas9 (SpCas9-HF) (Kleinstiver et al., 2016) and enhanced specificity SpCas9 (eSpCas9) (Slaymaker et al.”
BackgroundAnti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies
Marino, N. D., Pinilla-Redondo, R., Csörgő, B., & Bondy-Denomy, J. (2020) · Nature Methods · doi:10.1038/s41592-020-0771-6 · Cited by 246
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
Single Cas9 nickase induced generation of NRAMP1 knockin cattle with reduced off-target effects
Gao, Y., Wu, H., Wang, Y., Liu, X., Chen, L., Li, Q., Cui, C., Liu, X., Zhang, J., & Zhang, Y. (2017) · Genome Biology · doi:10.1186/s13059-016-1144-4 · Cited by 230
Daisy-chain gene drives for the alteration of local populations
Noble, C., Min, J., Olejarz, J., Buchthal, J., Chavez, A., Smidler, A. L., DeBenedictis, E. A., Church, G. M., Nowak, M. A., & Esvelt, K. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716358116 · Cited by 233
“We consider this reasonable because most elements in the daisy chain can consist of only guide RNAs, which should confer much lower costs than typical payloads[14][15]; moreover, potentially costly off-target cutting is minimal when using high-fidelity Cas9 variants[16] [17].”
BackgroundPartial DNA-guided Cas9 enables genome editing with reduced off-target activity
Yin, H., Song, C.-Q., Suresh, S., Kwan, S.-Y., Wu, Q., Walsh, S., Ding, J., Bogorad, R. L., Zhu, L. J., Wolfe, S. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2559 · Cited by 240
Direct observation of DNA target searching and cleavage by CRISPR-Cas12a
Jeon, Y., Choi, Y. H., Jang, Y., Yu, J., Goo, J., Lee, G., Jeong, Y. K., Lee, S. H., Kim, I.-S., Kim, J.-S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05245-x · Cited by 239
Application of CRISPR/Cas9 in Crop Quality Improvement
Liu, Q., Yang, F., Zhang, J., Liu, H., Rahman, S., Islam, S., Ma, W., & She, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084206 · Cited by 216
CRISPR base editors: genome editing without double-stranded breaks
Eid, A., Alshareef, S., & Mahfouz, M. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170793 · Cited by 224
Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes
Hess, G. T., Tycko, J., Yao, D., & Bassik, M. C. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.029 · Cited by 234
Design of highly functional genome editors by modelling CRISPR–Cas sequences
Ruffolo, J. A., Nayfach, S., Gallagher, J. P., Bhatnagar, A., Beazer, J., Hussain, R., Russ, J., Yip, J., Hill, E., Pačesa, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09298-z · Cited by 246
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
Tao, J., Bauer, D. E., & Chiarle, R. (2023) · Nature Communications · doi:10.1038/s41467-023-35886-6 · Cited by 207
Principles, Applications, and Biosafety of Plant Genome Editing Using CRISPR-Cas9
El-Mounadi, K., Morales-Floriano, M. L., & Garcia-Ruiz, H. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.00056 · Cited by 219
Jasin, M., & Haber, J. E. (2016) · DNA Repair · doi:10.1016/j.dnarep.2016.05.001 · Cited by 223
Minimal PAM specificity of a highly similar SpCas9 ortholog
Chatterjee, P., Jakimo, N., & Jacobson, J. M. (2018) · Science Advances · doi:10.1126/sciadv.aau0766 · Cited by 228
Varshney, G. K., Carrington, B., Pei, W., Bishop, K., Chen, Z., Fan, C., Xu, L., Jones, M., LaFave, M. C., Ledin, J., et al. (2016) · Nature Protocols · doi:10.1038/nprot.2016.141 · Cited by 228
Zou, Y., Sun, X., Yang, Q., Zheng, M., Shimoni, O., Ruan, W., Wang, Y., Zhang, D., Yin, J., Huang, X., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm8011 · Cited by 227
Jensen, K. T., Fløe, L., Petersen, T. S., Huang, J., Xu, F., Bolund, L., Luo, Y., & Lin, L. (2017) · FEBS Letters · doi:10.1002/1873-3468.12707 · Cited by 225
Wolter, F., Schindele, P., & Puchta, H. (2019) · BMC Plant Biology · doi:10.1186/s12870-019-1775-1 · Cited by 214
CRISPR-Cas9 nuclear dynamics and target recognition in living cells
Ma, H., Tu, L.-C., Naseri, A., Huisman, M., Zhang, S., Grunwald, D., & Pederson, T. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201604115 · Cited by 218
“It will be intriguing to examine whether new Cas orthologues (Hou et al., 2013; Ran et al., 2015; Zetsche et al., 2015) or S. pyogenes Cas9 variants with increased specificity (Kleinstiver et al., 2016; Slaymaker et al., 2016) sensitize target discrimination by altering residence times.”
BackgroundT-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 215
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Tsuchida, C. A., Brandes, N., Bueno, R., Trinidad, M., Mazumder, T., Yu, B., Hwang, B., Chang, C., Liu, J., Sun, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.041 · Cited by 209
Biological plasticity rescues target activity in CRISPR knock outs
Smits, A. H., Ziebell, F., Joberty, G., Zinn, N., Mueller, W. F., Clauder-Münster, S., Eberhard, D., Fälth Savitski, M., Grandi, P., Jakob, P., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0614-5 · Cited by 219
Mikuni, T., Nishiyama, J., Sun, Y., Kamasawa, N., & Yasuda, R. (2016) · Cell · doi:10.1016/j.cell.2016.04.044 · Cited by 214
Cao, J., Wu, L., Zhang, S.-M., Lu, M., Cheung, W. K. C., Cai, W., Gale, M., Xu, Q., & Yan, Q. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw660 · Cited by 217
Cartilage repair by mesenchymal stem cells: Clinical trial update and perspectives
Lee, W. Y.-W., & Wang, B. (2017) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2017.03.005 · Cited by 207
Nishiyama, J., Mikuni, T., & Yasuda, R. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.004 · Cited by 215
Catarino, R. R., & Stark, A. (2018) · Genes & Development · doi:10.1101/gad.310367.117 · Cited by 210
Recent advances in the CRISPR genome editing tool set
Moon, S. B., Kim, D. Y., Ko, J.-H., & Kim, Y.-S. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0339-7 · Cited by 203
Koblan, L. W., Arbab, M., Shen, M. W., Hussmann, J. A., Anzalone, A. V., Doman, J. L., Newby, G. A., Yang, D., Mok, B., Replogle, J. M., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00938-z · Cited by 211
On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals
Mojica, F. J. M., & Montoliu, L. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.005 · Cited by 189
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
CRISPR off-target analysis in genetically engineered rats and mice
Anderson, K. R., Haeussler, M., Watanabe, C., Janakiraman, V., Lund, J., Modrusan, Z., Stinson, J., Bei, Q., Buechler, A., Yu, C., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0011-5 · Cited by 216
PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1
Qian, X., Li, X., Shi, Z., Xia, Y., Cai, Q., Xu, D., Tan, L., Du, L., Zheng, Y., Zhao, D., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.006 · Cited by 205
The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit
Murugan, K., Babu, K., Sundaresan, R., Rajan, R., & Sashital, D. G. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.007 · Cited by 205
“Future studies of this mechanism will help to illuminate these disparate specificities, and could facilitate the design of Type V effectors with higher specificity, as has been achieved for Cas9 (Chen et al., 2017; Kleinstiver et al., 2016a; Slaymaker et al., 2016).”
BackgroundInfluentialKantor, B., Tagliafierro, L., Gu, J., Zamora, M. E., Ilich, E., Grenier, C., Huang, Z. Y., Murphy, S., & Chiba-Falek, O. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.019 · Cited by 204
Abadi, S., Yan, W. X., Amar, D., & Mayrose, I. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005807 · Cited by 197
CRISPR Cpf1 proteins: structure, function and implications for genome editing
Safari, F., Zare, K., Negahdaripour, M., Barekati-Mowahed, M., & Ghasemi, Y. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0298-7 · Cited by 193
“renders Cpf1a plausible candidate for therapeutic applications in future [30].”
BackgroundInfluentialGene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
“85% of wild-type activity, but almost eliminated off-target effects(186).”
BackgroundCRISPR/Cas9 Immune System as a Tool for Genome Engineering
Hryhorowicz, M., Lipiński, D., Zeyland, J., & Słomski, R. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0427-5 · Cited by 178
“Another way to enhance CRISPR targeting specificity with engineering Cas9 has been described by Kleinstiver et al. (2016).”
BackgroundBoyle, E. A., Andreasson, J. O. L., Chircus, L. M., Sternberg, S. H., Wu, M. J., Guegler, C. K., Doudna, J. A., & Greenleaf, W. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700557114 · Cited by 201
Wang, Z., Wang, S., Li, D., Zhang, Q., Li, L., Zhong, C., Liu, Y., & Huang, H. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.12884 · Cited by 195
CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids
Hendriks, D., Clevers, H., & Artegiani, B. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.10.014 · Cited by 192
Improving Plant Genome Editing with High-Fidelity xCas9 and Non-canonical PAM-Targeting Cas9-NG
Zhong, Z., Sretenovic, S., Ren, Q., Yang, L., Bao, Y., Qi, C., Yuan, M., He, Y., Liu, S., Liu, X., et al. (2019) · Molecular Plant · doi:10.1016/j.molp.2019.03.011 · Cited by 196
Widespread anti-CRISPR proteins in virulent bacteriophages inhibit a range of Cas9 proteins
Hynes, A. P., Rousseau, G. M., Agudelo, D., Goulet, A., Amigues, B., Loehr, J., Romero, D. A., Fremaux, C., Horvath, P., Doyon, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05092-w · Cited by 198
A chemical-inducible CRISPR–Cas9 system for rapid control of genome editing
Liu, K. I., Ramli, M. N. B., Woo, C. W. A., Wang, Y., Zhao, T., Zhang, X., Yim, G. R. D., Chong, B. Y., Gowher, A., Chua, M. Z. H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2179 · Cited by 197
Prediction of the sequence-specific cleavage activity of Cas9 variants
Kim, N., Kim, H. K., Lee, S., Seo, J. H., Choi, J. W., Park, J., Min, S., Yoon, S., Cho, S.-R., & Kim, H. H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0537-9 · Cited by 198
Singh, D., Mallon, J., Poddar, A., Wang, Y., Tippana, R., Yang, O., Bailey, S., & Ha, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718686115 · Cited by 199
Highly Parallel Profiling of Cas9 Variant Specificity
Schmid-Burgk, J. L., Gao, L., Li, D., Gardner, Z., Strecker, J., Lash, B., & Zhang, F. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.02.023 · Cited by 197
“Cas9 variant validation and combinatorial mutagenesis Top hits from the pooled variant screen that exhibited both high on-target efficiency and high specificity were individually cloned into pX165 (Ran et al., 2013) and tested at additional target sites in HEK293T cells, including sites that were previously observed t…”
InfluentialBase editors for simultaneous introduction of C-to-T and A-to-G mutations
Sakata, R. C., Ishiguro, S., Mori, H., Tanaka, M., Tatsuno, K., Ueda, H., Yamamoto, S., Seki, M., Masuyama, N., Nishida, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0509-0 · Cited by 196
CRISPR-Cas systems for diagnosing infectious diseases
Kostyusheva, A., Brezgin, S., Babin, Y., Vasilyeva, I., Glebe, D., Kostyushev, D., & Chulanov, V. (2022) · Methods · doi:10.1016/j.ymeth.2021.04.007 · Cited by 181
Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss
György, B., Nist-Lund, C., Pan, B., Asai, Y., Karavitaki, K. D., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Solanes, P., Spataro, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0500-9 · Cited by 196
“To increase specificity of gene editing, truncated gRNAs 7 or high fidelity Cas9 variants 8-10 have been developed.”
Self-citationZhang, Q., Xing, H.-L., Wang, Z.-P., Zhang, H.-Y., Yang, F., Wang, X.-C., & Chen, Q.-J. (2018) · Plant Molecular Biology · doi:10.1007/s11103-018-0709-x · Cited by 187
High-Level dCas9 Expression Induces Abnormal Cell Morphology in Escherichia coli
Cho, S., Choe, D., Lee, E., Kim, S. C., Palsson, B., & Cho, B.-K. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00462 · Cited by 190
Genome Editing in Plants: Exploration of Technological Advancements and Challenges
Vats, S., Kumawat, S., Kumar, V., Patil, G. B., Joshi, T., Sonah, H., Sharma, T. R., & Deshmukh, R. (2019) · Cells · doi:10.3390/cells8111386 · Cited by 190
“Cas9 variants with 3-4 amino acid substitutions, which do not tolerate even a single mismatch has also been developed [164].”
BackgroundZhou, W., Cui, H., Ying, L., & Yu, X. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201806941 · Cited by 195
Precision genome editing in the CRISPR era
Salsman, J., & Dellaire, G. (2017) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0137 · Cited by 185
CRISPR-SKIP: programmable gene splicing with single base editors
Gapinske, M., Luu, A., Winter, J., Woods, W. S., Kostan, K. A., Shiva, N., Song, J. S., & Perez-Pinera, P. (2018) · Genome Biology · doi:10.1186/s13059-018-1482-5 · Cited by 184
An efficient auxin-inducible degron system with low basal degradation in human cells
Li, S., Prasanna, X., Salo, V. T., Vattulainen, I., & Ikonen, E. (2019) · Nature Methods · doi:10.1038/s41592-019-0512-x · Cited by 193
Structural biology of CRISPR–Cas immunity and genome editing enzymes
Wang, J. Y., Pausch, P., & Doudna, J. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00739-4 · Cited by 187
Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity
Cromwell, C. R., Sung, K., Park, J., Krysler, A. R., Jovel, J., Kim, S. K., & Hubbard, B. P. (2018) · Nature Communications · doi:10.1038/s41467-018-03927-0 · Cited by 190
CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Transcriptional Regulation
Cai, R., Lv, R., Shi, X., Yang, G., & Jin, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914865 · Cited by 174
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 181
“…be edited given that it has a different PAM than Cas9, Cas12a-mediated editing has several advantages over Cas9: it is significantly more specific (Kleinstiver et al., 2016b; Kim et al., 2017b), which is important for therapeutic applications; it offers a simplified guide design because it does…”
BackgroundMethodHighly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3′-overhang
Bin Moon, S., Lee, J. M., Kang, J. G., Lee, N.-E., Ha, D.-I., Kim, D. Y., Kim, S. H., Yoo, K., Kim, D., Ko, J.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06129-w · Cited by 182
Consumer acceptance of food crops developed by genome editing
Ishii, T., & Araki, M. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1974-2 · Cited by 186
Aljabali, A. A. A., El‐Tanani, M., & Tambuwala, M. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105338 · Cited by 232
The CRISPR/Cas9 system and its applications in crop genome editing
Bao, A., Burritt, D. J., Chen, H., Zhou, X., Cao, D., & Tran, L.-S. P. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1554621 · Cited by 185
“For example, high-fidelity Cas9 nucleases, like SpCas9-HF1 and eSpCas9, have been designed to reduce nonspecific DNA editing [62,63].”
BackgroundCRISPR–Cas: a tool for cancer research and therapeutics
Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 178
Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice
Chai, A. C., Cui, M., Chemello, F., Li, H., Chen, K., Tan, W., Atmanli, A., McAnally, J. R., Zhang, Y., Xu, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02176-5 · Cited by 184
Yeh, W.-H., Shubina-Oleinik, O., Levy, J. M., Pan, B., Newby, G. A., Wornow, M., Burt, R., Chen, J. C., Holt, J. R., & Liu, D. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9101 · Cited by 185
Holme, I. B., Gregersen, P. L., & Brinch-Pedersen, H. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.01468 · Cited by 164
Yang, Q., Zhou, Y., Chen, J., Huang, N., Wang, Z., & Cheng, Y. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s286221 · Cited by 178
Bak, R. O., Gomez-Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 176
Deciphering, Communicating, and Engineering the CRISPR PAM
Leenay, R. T., & Beisel, C. L. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.024 · Cited by 180
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.